Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraltek-58 for House Dust Mite Allergic Rhinitis and Asthma
NCT07348302Phase 3Recruiting
- Sponsor
- Inmunotek
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of dermatophagoides pteronyssinus extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Inmunotek. Primary endpoint: Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score. Started Apr 2025; status: recruiting.
02
Drugs
dermatophagoides pteronyssinus extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT07348302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348302.